5 April 2006

Preliminary Results for year ended 31 December 2005

Cyprotex PLC, a drug discovery technology and information company, today reports its preliminary results for the year ended 31 December 2005.

Highlights

• Revenue increased over 27% to £2.70 million from £2.12 million
• Gross profits up more than 36% to £2.3 million up from £1.7 million
• Gross margins rose to 85%, compared with 80%
• Cash resources were carefully guarded. Year end free cash amounted to £0.7m, despite significant capital investment in process automation, capability and capacity
• The loss on ordinary activities after taxation was £0.9m down from £1.3m in 2004, a 30% reduction
• A rapidly expanding customer base has ensured the Group does not have a high dependence on any single client; the largest of which contributed less than 20 % of total revenues in 2005

Commenting on the results, Robert Morrisson Atwater, Chairman and Chief Executive Officer of Cyprotex PLC, said:

"Anticipating a continued high-level of "repeat business" and further enlargement of the customer base and contract type amid continued market expansion, Cyprotex sees an excellent opportunity for further significant growth in 2006."

Click here to download the full statement as a PDF document.

For further information, please contact:

Media enquiries: